PAR-24-044: NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants to small businesses. Applications closed on November 17, 2025.
From the official notice on Grants.gov, last changed November 17, 2025. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR41 / R42
- Clinical trialsRequired
- Funded byNINDS
- Median yearly award$500,000
- Typical project length1.5 years
- R41, Small Business Technology Transfer (STTR) Phase I. A small business and a research institution test the feasibility of a technology together. Other open R41 notices.
- R42, Small Business Technology Transfer (STTR) Phase II. Full development of an STTR project after Phase I. Other open R42 notices.
Projects funded under PAR-24-044 were run by National Institute of Neurological Disorders and Stroke (NINDS, 2 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
This notice replaced PAR-18-617.
Application due dates, page limits and budget limits are set in the notice. Read PAR-24-044 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-21-267 | July 16, 2021 | Closed November 26, 2023 | Closed |
Key dates
| Posted | November 27, 2023 |
|---|---|
| Deadline | November 17, 2025 |
| Archived by Grants.gov | November 18, 2025 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following:Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Is this a realistic fit?
- Most of the program's money (76% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
(Reissue of PAR-18-617) The purpose of this funding opportunity announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Technology Transfer (STTR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The projects must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Only STTR Phase II and Fast-Track applications are supported under this program. STTR Phase I applications are only accepted as part of a Fast-track application.
Funded under PAR-24-044 so far
NIH funded 2 projects under PAR-24-044 in fiscal 2025 to 2026, at 2 institutions. The median yearly award was $500,000.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Portable TMS-EEG device for bedside detection of covert consciousness | Intrinsic Powers, Inc. | 2026 | $467,771 |
| Development and assessment of a powered prosthetic digit system with novel wrist-based control and integrated sensory feedback | Neurorobotic Technologies, LLC | 2026 | $500,000 |
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before
From fiscal 2021 to 2025, Extramural Research Programs in the Neurosciences and Neurological Disorders (93.853) awarded $9.1 billion across 8,641 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 203 | $288 million |
| The Regents of the University of California, San Francisco | California | 248 | $277 million |
| The Johns Hopkins University | Maryland | 230 | $276 million |
| The Trustees of Columbia University in the City of New York | New York | 188 | $226 million |
| Regents of the University of Michigan | Michigan | 179 | $221 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-24-044 still open?
No. It closed on November 17, 2025.
Who can apply for NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)?
Closed November 17, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-24-044?
NIH RePORTER lists 2 projects funded under PAR-24-044 in fiscal 2025 to 2026, at 2 institutions. The most were at Intrinsic Powers, Inc., Neurorobotic Technologies, LLC.
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before?
The largest recipients over five fiscal years were The General Hospital Corporation, The Regents of the University of California, San Francisco, The Johns Hopkins University. The program made 8,641 awards worth $9.1 billion in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)